跳至主要内容
临床试验/NCT06126328
NCT06126328已完成2 期

EASE Study: A Randomized, Controlled Study to EvAluate the Safety and Effectiveness of the Materna Prep Device to Pre-stretch the Vaginal Canal and Pelvic Floor Muscles in Preparation for Vaginal Delivery

Materna Medical29 个研究点 分布在 1 个国家目标入组 214 人开始时间: 2021年9月8日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
214
试验地点
29
主要终点
The occurrence of pelvic muscle injury, defined as complete or partial detachment of the levator ani muscle diagnosed via ultrasound imagingmuscle diagnosed via ultrasound imaging

研究概览

简要总结

This study is designed to evaluate the safety and effectiveness of the Materna Prep Device in reducing pelvic muscle injuries during vaginal delivery.

Subjects are randomized to Materna Prep Device or Standard of Care without use of the Materna Prep Device

Intervention with the Materna Prep Device is expected to be a one-time use of approximately 30-90 minutes during the 1st stage of labor.

Subject participation in the study is targeted to be 3 months from the time of the use of the device during delivery with optional long-term follow-up.

详细描述

Vaginal delivery is a major risk factor for pelvic floor dysfunction. Clinical aspects of pelvic floor dysfunction include pelvic organ prolapse, sexual dysfunction, and fecal and urinary incontinence. Trauma to the pelvic structures occurs as the fetal head passes through the vaginal canal, especially with acute distension at the time of crowning - the exiting of the fetal head.

The Materna Prep Device is a single-use, semi-automated dilator used during the first phase of labor in order to prepare the vaginal canal for vaginal delivery. By slowly pre-stretching the vagina and surrounding pelvic tissues during labor, the device is essentially dictating the strain rate of the tissue during labor. In previous feasibility studies, the elastic recovery of the tissue has been shown to be on the order of several hours, allowing the benefits of pre-stretching the vagina and surrounding pelvic tissues to last throughout labor. The device is intended to be removed prior to the initiation of the second stage of labor, for delivery to occur unobstructed.

The target patient population for this study is nulliparous women entering the first phase of labor and scheduled for vaginal delivery with an epidural.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
Single (Outcomes Assessor)

盲法说明

Ultrasound images are assessed by physicians blinded to randomization

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Subject is scheduled for vaginal birth.
  • Subject is gestating a single fetus.
  • Subject is nulliparous, or had a previous pregnancy terminated within 24 weeks gestation.
  • Subject is able and willing to comply with the protocol required follow-up visits.
  • Subject is able and willing to provide written informed consent prior to enrollment.
  • In the opinion of the Investigator, the subject has sufficient mental capacity to understand the informed consent form (ICF), comply with the protocol requirements, and provide clinically relevant and reliable feedback regarding their experience with the device.
  • Subject receives epidural anesthesia during labor prior to enrollment.
  • Subject is 18 years of age or older at time of consent.

排除标准

  • Subject has high likelihood of less than 1 hour of potential device dilation time after she arrives at the hospital.
  • Subject is planning or requires a Caesarean-section prior to randomization.
  • Subject begins labor with less than 36 weeks gestation.
  • Subject has a neurological disorder that could cause pelvic floor dysfunction, such as multiple sclerosis or spinal cord injury.
  • Subject has a collagen-associated disorder that affects tissue elasticity, such as scleroderma or Ehlers-Danlos syndrome.
  • Subject has a localized (genital tract) or systemic infection.
  • Subject has a medical history which could lead to pelvic floor dysfunction, such as prior pelvic fractures, pelvic soft tissue injuries, or vaginal surgery.
  • Subject has any general health condition or systemic disease that may represent, in the opinion of the Investigator, a potential increased risk associated with device use or pregnancy.
  • Subject has placenta previa or vasa previa.
  • Subject has known significant chromosomal or structural fetal anomalies.
  • Subject has a category 2 and/or 3 fetal tracing that is unresolved.

结局指标

主要结局

The occurrence of pelvic muscle injury, defined as complete or partial detachment of the levator ani muscle diagnosed via ultrasound imagingmuscle diagnosed via ultrasound imaging

时间窗: 3-month Follow-up

Use transperineal ultrasound to identify levator ani muscle detachment

次要结局

  • C-Sections(Day of Delivery)
  • The occurrence of pelvic muscle injury, defined as complete detachment of the levator ani muscle diagnosed via ultrasound imaging(3-month Follow-up)
  • Length of 2nd Stage Labor(Day of Delivery)
  • Perineal Lacerations(Day of Delivery)
  • Obstetric anal sphincter injury - OASI(3-month Follow-up)
  • Infant APGAR scores(Day of Delivery)
  • Levator Hiatal Area(3-month Follow-up)
  • Qualitative pelvic health feedback(3-month Follow-up)
  • First Push to Delivery(Day of Delivery)
  • Operative Delivery(Day of Delivery)

研究者

发起方
Materna Medical
申办方类型
Industry
责任方
Sponsor

研究点 (29)

Loading locations...

相似试验

Materna Prep Study Phase II | 临床试验